Novocure to Present at Two Upcoming Investor Conferences in December
November 22 2017 - 7:30AM
Business Wire
Novocure (NASDAQ:NVCR) announced today that it will participate
in two upcoming investor conferences in December.
Asaf Danziger, Novocure’s Chief Executive Officer, and Wilco
Groenhuysen, Novocure’s Chief Financial Officer, will participate
in a fireside chat at the Nasdaq 37th International Investor
Conference on December 5, 2017, in London. Mr. Danziger and Mr.
Groenhuysen’s presentation will begin at 8:15 a.m. GMT (3:15 a.m.
EST) and will be followed by a Q&A session.
A live audio webcast of the presentation can be accessed from
the Investor Relations page of Novocure’s website,
www.novocure.com/investor-relations, and will be available for
replay for at least 14 days following the presentation.
Additionally, William Doyle, Novocure’s Executive Chairman, will
participate in the Global Mizuho Investor Conference on December 5,
2017, in New York City. Mr. Doyle will participate in one-on-one
meetings with investors throughout the day.
All presentation materials can be accessed from the Investor
Relations page of Novocure’s website,
www.novocure.com/investor-relations, and will be available for at
least 14 days following the events.
About Novocure
Novocure is an oncology company developing a profoundly
different cancer treatment utilizing a proprietary therapy called
Tumor Treating Fields, the use of electric fields tuned to specific
frequencies to disrupt solid tumor cancer cell division. Novocure’s
commercialized product is approved for the treatment of adult
patients with glioblastoma. Novocure has ongoing or completed
clinical trials investigating Tumor Treating Fields in brain
metastases, non-small cell lung cancer, pancreatic cancer, ovarian
cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in
Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City.
Additionally, the company has offices in Germany, Switzerland,
Japan and Israel. For additional information about the company,
please visit www.novocure.com or follow us at
www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, development of potential products,
interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market
prospects for its products, and other statements regarding matters
that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements
such as “anticipate,” “estimate,” “expect,” “project,” “intend,”
“plan,” “believe” or other words and terms of similar meaning.
Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 23, 2017, with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171122005042/en/
Media and InvestorsNovocureAshley Cordova,
212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024